Abstract: a-Hemoglobin-stabilizing protein (AHSP) is an abundant erythroid-specific chaperone protein that facilitates incorporation of nascent a-globin into hemoglobin A. We characterized AHSP expression by immunohistochemistry in a panel of 100 neoplastic and reactive bone marrow biopsies and splenic tissue with extramedullary hematopoiesis and compared it with established erythroid markers CD71 and CD235a. In all cases, AHSP expression was limited to physiological nucleated erythroid precursors (EPs) and blasts in erythroid leukemias. Although CD71 also stained EPs, it additionally stained nonerythroid malignant cells to varying extents in acute leukemia, diffuse large B-cell lymphoma, metastatic carcinomas, and small round blue cell tumors. In contrast, CD235a staining was erythroid-specific but stained non-nucleated red blood cells in all specimens, limiting its utility. We conclude that AHSP is superior to CD71 and CD235a for detecting normal and neoplastic nucleated EPs.
I dentification of erythroid precursors (EPs) in bone marrow biopsies is essential for lineage assignment of immature precursors or blasts, assessment of the myeloid:erythroid ratio, and evaluation of topographic features indicative of myelodysplasia. Morphologic assessment of hematoxylin and eosin-stained samples can help identify EPs in many circumstances. However, specimens with erythroid dyspoiesis, increased immature forms, topographic disarray, or nonhematopoietic lesions can be especially challenging and may require the use of immunohistochemical erythroid stains.
Antibodies currently used clinically to identify EPs include CD235a, CD71, and hemoglobin A (HbA). Each of these antibodies has specific limitations. CD235a and HbA label both EPs and mature, non-nucleated red blood cells (RBCs), creating excessive background staining in specimens with extensive hemorrhage. Furthermore, CD235a may not stain the most immature EPs. 1 CD71 [transferrin receptor 1 (TfR1)] has recently been shown to label EPs and not non-nucleated RBCs, potentially overcoming the limitations of CD235a. 2, 3 However, CD71 expression occurs in a wide range of cells, such as activated T lymphocytes, T-lymphocyte and B-lymphocyte precursors, epithelial cells (including keratinocytes), and myocytes, and is generally considered to be a marker for rapidly proliferating cells. 4 CD71 expression in bone marrow has been reported in acute myeloid and lymphoid leukemias and a variety of lymphomas involving the bone marrow. Thus, the nonspecific nature of CD71 could confound interpretation in diagnostically challenging cases or in limited samples. For these reasons, more sensitive and specific methods to identify EPs in clinical samples are needed to improve the accuracy of hematopathologic diagnoses. This need could be fulfilled by an antibody directed against an erythroid lineage-specific antigen that is highly expressed in EPs and downregulated upon their subsequent maturation into anucleate RBCs. We hypothesized that a-hemoglobin-stabilizing protein (AHSP), a recently discovered erythroid protein, would fulfill these requirements.
AHSP is a 12 kDa chaperone protein that binds nascent a-globin and facilitates its incorporation into HbA. 5 AHSP binds reversibly with free a-globin, preventing its aggregation and stabilizing its structure before binding b-globin to form HbA. 6 Loss of AHSP expression in a murine model results in globin precipitation with ineffective erythropoiesis. 6, 7 AHSP is expressed at high levels in lineage-committed EPs that are actively synthesizing Hb. In anucleate reticulocytes and mature RBCs, AHSP synthesis declines, and the protein is degraded. These properties make AHSP an ideal candidate for marking nucleated EPs.
We characterized AHSP expression in bone marrow biopsies and splenic specimens from adult and pediatric patients with a variety of hematopoietic neoplasms, metastatic nonhematopoietic cancers, and reactive conditions. Comparison with immunohistochemical staining of CD71 and CD235a on the same samples indicates that anti-AHSP staining is the superior approach for detecting EPs.
MATERIALS AND METHODS
All procedures were reviewed and approved by the Institutional Review Boards at the School of Medicine, University of Pennsylvania and the Children's Hospital of Philadelphia (CHOP). The number in each column refers to the number of specimens with positive staining for each category of cells. *Giant pronormoblasts are considered lesional cells for the purposes of this table. AML indicates acute myeloid leukemia; NA, not applicable; NOS, not otherwise specified.
Polyclonal antibody against full-length recombinant human AHSP was commercially prepared by Covance Research Products (Denver, PA).
Bone marrow biopsy and splenic specimens from reactive and neoplastic conditions were identified by searching the laboratory information systems of the Hospital of the University of Pennsylvania and CHOP. All adult biopsies were fixed in B5 and decalcified for 1 to 2 hours using RDO rapid decalcifying solution (Darlco, Oradell, NJ). Pediatric bone marrow biopsies (for cases of neuroblastoma, rhabdomyosarcoma, primitive neuroectodermal tumor, and retinoblastoma) were fixed in acetic acid-zincformalin and decalcified for 30 minutes using RDO rapid decalcifying solution (Darlco, Oradell, NJ). Splenic tissue was fixed in formalin. All samples were routinely embedded in paraffin. Immunohistochemical staining was performed on 4-mm-thick sections for AHSP (rabbit polyclonal; 1:8000), CD71 (Invitrogen, Grand Island, NY; H68.4; 1:1600), and CD235a (Dako, Carpinteria, CA; JC159; 1:1000). Deparaffinization, epitope retrieval with a pH9 buffer, and detection were performed on a Leica Bond-Max automated stainer. Staining was assessed visually in all specimens and categorized as "positive" or "negative" in each cell lineage, any neoplastic cells present, and noncellular background material. All stainings were performed in the same laboratory with adequate positive and negative controls, and all samples were reviewed by 2 pathologists (P.W.R., J.K.C.). Images included in this manuscript were obtained by scanning slides at Â 40 original magnification with an Aperio Scanscope CS; no color enhancement or alteration was performed on any image after scanning.
RESULTS
Immunohistochemical staining for AHSP, CD71, and CD235a was performed on 100 bone marrow samples representing a variety of neoplastic and reactive conditions and splenic tissue with extramedullary hematopoiesis; the results are detailed in Table 1 . In summary, AHSP stained EPs in all specimens tested and did not stain nonerythroid cells. AHSP demonstrates a cytoplasmic staining pattern and brightly labels nucleated EPs from early (pronormoblast) through orthochromatic normoblast stages. CD235a stained both non-neoplastic EPs and mature (anucleate) RBCs, confounding evaluation in specimens with extensive hemorrhage and in splenic tissue with extramedullary hematopoiesis and congestion. Like AHSP, CD71 stained EPs in all specimens tested; however, it also stained neoplastic cells in a subset of nonerythroid acute leukemias, diffuse large B-cell lymphomas (DLBCLs), metastatic carcinomas, and small round blue cell tumors. Neither AHSP nor CD71 stained non-nucleated RBCs.
AHSP specifically stained EPs in all normal bone marrow biopsies, all bone marrow biopsies with relative erythroid hyperplasia, and in all adult splenic samples with extramedullary hematopoiesis (Fig. 1 ). CD71 and CD235a also stained EPs in all of these specimens. In addition, acute erythroid leukemia blasts (both erythroleukemic and pure erythroid leukemic blasts) were positive for AHSP staining (Fig. 2) . CD71 and CD235a also stained erythroid blasts in all cases of acute erythroid leukemia. However, CD71 also stained blasts to varying degrees in every morphologic subset of acute myeloid leukemia (Fig. 3) and both acute Tlymphoblastic and B-lymphoblastic leukemia. In general, non-M6 acute myeloid leukemias stained less intensely with CD71 than did EPs. However, a minority of myeloid blasts stained strongly for this antigen at an intensity approximating that exhibited by EPs.
AHSP and CD71 antibodies performed comparably in specimens with myeloproliferative neoplasms and myelodysplastic syndromes, with both antibodies staining EPs in all bone marrow biopsies examined. All cases of primary myelofibrosis exhibited mildly increased staining of megakaryocytes by both AHSP and CD71; CD235a staining did not stain megakaryocytes (Fig. 4) . AHSP staining in megakaryocytes was variable between cases and between individual megakaryocytes within the same case.
CD71 expression was also noted in many bone marrow biopsies with metastatic malignancies, including DLBCL (4 of 5 cases, Figs. 5A-C) and carcinoma (2 of 4 cases, Figs. 5D-F) in adults, and neuroblastoma (5 of 5 cases) and rhabdomyosarcoma (1 of 3 cases) in children. CD71 staining ranged in intensity from dim to bright in metastatic lesions, but was equal to that observed in EPs in multiple cases. CD235a stained both EPs and nonnucleated RBCs and did not stain metastatic lesions.
Both AHSP and CD71 stained giant pronormoblasts in bone marrow biopsies from patients with parvovirus infection (Fig. 6) , whereas CD235a was negative in these cells, consistent with CD235a expression relatively late in erythroid development.
AHSP and CD71 both stained <1% of nonnucleated RBCs in all tested specimens, likely marking young reticulocytes that had recently extruded their nucleus. No increase in the frequency of positively staining non-nucleated RBCs was detected in biopsies with myelodysplasia stained with AHSP or CD71. In rare instances, AHSP-stained slides exhibited increased levels of background signal that was localized to noncellular proteinaceous fluid present in the specimens. This artifact was infrequent and was not overrepresented in any individual class of diagnoses. This finding is attributed to nonspecific binding of the polyclonal antibody to serum proteins and did not affect interpretation of cellular staining patterns.
DISCUSSION
Our results demonstrate that AHSP is a lineagespecific marker of nucleated EPs with improved specificity and equivalent sensitivity as compared with CD71 and CD235a. AHSP staining characteristics did not differ after various fixation protocols (B5, acetic acid-zinc-formalin, and formalin) and were not affected by routine decalcification procedures. In virtually every case, AHSP antibody stained only EPs and erythroid malignancies, whereas CD71 stained malignant cells in a subset of nonerythroid acute leukemias, DLBCL, and metastatic nonhematopoietic malignancies. This result is expected in light of the biological restriction of AHSP to the erythroid lineage as a necessary factor for the effective production of Hb.
In contrast, CD71 is a widely expressed protein involved in iron acquisition for most cell types. CD71 expression levels are particularly high in EPs to supply adequate levels of iron for Hb production. However, many rapidly dividing cells, including malignant ones, also exhibit relatively high levels of CD71 in order to supply iron to meet metabolic demands. 4 Although CD71 and AHSP stain nucleated EPs, analysis of CD235a staining patterns is confounded by staining of anucleate RBCs that frequently contaminate pathologic specimens. This effect is most pronounced in samples of splenic extramedullary hematopoiesis and in bone marrow biopsies with extensive hemorrhage. Thus, among current antigens used for detecting EPs in pathologic samples, only AHSP meets 2 important criteria: high specificity for the erythroid lineage and lack of staining in anucleate RBCs. These properties reflect the biological functions of AHSP. As a molecular chaperone for a-globin, AHSP expression coincides with Hb synthesis, which occurs specifically in erythroid tissues. 5, 8 As Hb synthesis declines during the reticulocyte stage of erythropoiesis, AHSP is no longer needed, and the protein is degraded.
Several other antibodies or antibody panels have been characterized as potential markers of EPs, highlighting the clinical need for such a stain. To our knowledge, all previously described markers other than CD235a stain non-EPs in bone marrow biopsies. A panel of 3 immunohistochemical markers targeting proteins whose expression is not limited to the erythroid lineage has also recently been described. 9 Although this panel of markers sensitively stains for EPs, it also marked blasts in a subset of nonerythroid acute leukemias. E-cadherin has also been shown to be expressed in EPs, although its expression is present in many epithelial cell types and also is not expressed in erythroleukemia. 10, 11 CD36, the thrombospondin receptor, is expressed not only in EPs but also in other cell types, including platelets, macrophages, and endothelial cells. 12, 13 CD71 has been previously reported to label blasts in a subset of non-erythroid acute leukemias in some studies but not in others. 2, 3 Our results confirm the former findings. Although CD71 expression is variable in nonerythroid malignancies, certain cases demonstrated CD71 expression in blasts that approximated levels exhibited by EPs. AHSP did not stain leukemic blasts in any cases of nonerythroid acute leukemias. AHSP staining was also limited to EPs in all cases of marrow involvement by DLBCL or nonhematopoietic malignancies, whereas CD71 stained the neoplastic cells in many of these cases. CD71 expression has been reported in a wide variety of activated or proliferating cell types, concordant with its biological role as the transferrin receptor. CD71 expression is likely upregulated in these cases secondary to increased iron demand in these rapidly proliferating cells.
Detection of AHSP in megakaryocytes associated with primary myelofibrosis is of uncertain etiology. Nonspecific staining is unlikely, as the antibody does not stain normal megakaryocytes in control specimens or bone marrow affected by B-cell lymphoma or parvovirus. It is possible that the pathologic megakaryocytes in primary myelofibrosis aberrantly express AHSP and occasionally CD71 as well, reflecting dysmegakaryopoiesis with derepression of an erythroid gene expression program. Erythroid and megakaryocytic lineages derive from a common bipotential progenitor and express overlapping sets of hematopoietic transcription factors. 14 Megakaryocytes in primary myelofibrosis have been demonstrated to aberrantly express multiple genes and miRNAs; however, AHSP has never been specifically studied. 15, 16 Importantly, AHSP did not stain blasts in acute megakaryocytic leukemia, whereas CD71 marked them brightly.
AHSP and CD71 both demonstrated intense staining of giant pronormoblasts in cases of parvovirus infection, whereas CD235a does not. Negative CD235a expression and CD71 positivity in infected giant pronormoblasts has previously been reported. 1,2 AHSP positivity in giant pronormoblasts confirms the ability of AHSP to mark EPs that are in the earliest stages of the erythroid lineage.
In addition to its potential clinical utility as a specific immunohistochemical marker of EPs, AHSP expression may be useful in other clinical and research settings. For example, further characterization of AHSP as an intracellular flow cytometric marker to identify acute erythroid leukemias and potentially help differentiate between morphologic subtypes (erythroleukemia vs. acute erythroid leukemia) is one area of potential study.
In summary, AHSP is a novel marker of EPs whose biological role as a chaperone protein necessary for Hb formation confers lineage specificity and whose expression is limited to nucleated EPs. AHSP may be useful in many clinical scenarios including assigning lineage to neoplastic or reactive immature cells and identifying EPs in dyspoietic marrows.
